EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy

Emanuele Cerulli Irelli, Enrico Cocchi, Alessandra Morano, Joanna Gesche, Roberto H Caraballo, Simona Lattanzi, Gionata Strigaro, Cecilia Catania, Edoardo Ferlazzo, Angelo Pascarella, Sara Casciato, Pierpaolo Quarato und 16 weitere

JAMA Neurology · 2023

DOI: 10.1001/jamaneurol.2023.3400 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Neurology, 2023. Verfasst von Emanuele Cerulli Irelli und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Neurosciences, Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance After the recent limitations to prescribing valproate, many studies have highlighted the challenging management of female patients of reproductive age with idiopathic generalized epilepsy (IGE). However, no study, to the authors’ knowledge, has addressed the comparative effectiveness of alternative antiseizure medications (ASMs) in these patients.

Objective

To compare the effectiveness and safety of levetiracetam and lamotrigine as initial monotherapy in female patients of childbearing age with IGE. Design, Setting, and Participants This was a multicenter, retrospective, comparative effectiveness cohort study analyzing data from patients followed up from 1994 to 2022. Patients were recruited from 22 primary, secondary, and tertiary adult and child epilepsy centers from 4 countries. Eligible patients were female individuals of childbearing age, diagnosed with IGE according to International League Against Epilepsy (2022) criteria and who initiated levetiracetam or lamotrigine as initial monotherapy. Patients were excluded due to insufficient follow-up after ASM prescription. Exposures Levetiracetam or lamotrigine as initial monotherapy. Main Outcomes and Measures Inverse probability of treatment weighting (IPTW)–adjusted Cox proportional hazards regression was performed to compare treatment failure (TF) among patients who received levetiracetam or lamotrigine as initial monotherapy.

Results

A total of 543 patients were included in the study, with a median (IQR) age at ASM prescription of 17 (15-21) years and a median (IQR) follow-up of 60 (24-108) months. Of the study population, 312 patients (57.5%) were prescribed levetiracetam, and 231 (42.5%) were prescribed lamotrigine. An IPTW-adjusted Cox model showed that levetiracetam was associated with a reduced risk of treatment failure after adjustment for all baseline variables (IPTW-adjusted hazard ratio [HR], 0.77; 95% CI, 0.59-0.99; P = .04). However, after stratification according to different IGE syndromes, the higher effectiveness of levetiracetam was confirmed only in patients with juvenile myoclonic epilepsy (JME; IPTW-adjusted HR, 0.47; 95% CI, 0.32-0.68; P < .001), whereas no significant differences were found in other syndromes. Patients treated with levetiracetam experienced adverse effects more frequently compared with those treated with lamotrigine (88 of 312 [28.2%] vs 42 of 231 [18.1%]), whereas the 2 ASMs had similar retention rates during follow-up (IPTW-adjusted HR, 0.91; 95% CI, 0.65-1.23; P = .60). Conclusions and Relevance Results of this comparative effectiveness research study suggest the use of levetiracetam as initial alternative monotherapy in female patients with JME. Further studies are needed to identify the most effective ASM alternative in other IGE syndromes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyAnticonvulsantsRetrospective StudiesLamotrigineCohort StudiesChildHumansImmunoglobulin EAdultEpilepsy, GeneralizedLevetiracetamFemale

Substanzen

LevetiracetamLamotrigineAnticonvulsantsImmunoglobulin E

Autor:innen und Institutionen

  • Department of Human Neurosciences, Sapienza University, Rome, Italy.
  • Department of Precision Medicine and Genomics, Department of Medicine, Columbia University, New York, New York.
  • Department of Neurology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Neurology, Hospital de Pediatría "Prof. Dr. Juan P Garrahan", Buenos Aires, Argentina.
  • Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.

Zitieren

APA

Cerulli Irelli, E., Cocchi, E., Morano, A., Gesche, J., Caraballo, R. H., Lattanzi, S., Strigaro, G., Catania, C., Ferlazzo, E., Pascarella, A., Casciato, S., Quarato, P., Pizzanelli, C., Pulitano, P., Giuliano, L., Viola, V., Mostacci, B., Fortunato, F., Marini, C., …, & Women With Epilepsy Treatment Options and Research (WETOR) Study Group (2023). Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.3400

Vancouver

Cerulli Irelli E, Cocchi E, Morano A, Gesche J, Caraballo RH, Lattanzi S, et al. Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy. JAMA Neurology. 2023. doi:10.1001/jamaneurol.2023.3400

BibTeX
@article{CerulliIrelli2023,
  author = {Cerulli Irelli, Emanuele and Cocchi, Enrico and Morano, Alessandra and Gesche, Joanna and Caraballo, Roberto H and Lattanzi, Simona and Strigaro, Gionata and Catania, Cecilia and Ferlazzo, Edoardo and Pascarella, Angelo and Casciato, Sara and Quarato, Pierpaolo and Pizzanelli, Chiara and Pulitano, Patrizia and Giuliano, Loretta and Viola, Veronica and Mostacci, Barbara and Fortunato, Francesco and Marini, Carla and Di Gennaro, Giancarlo and Gambardella, Antonio and Labate, Angelo and Operto, Francesca F and Giallonardo, Anna T and Baykan, Betul and Beier, Christoph P and Di Bonaventura, Carlo and Women With Epilepsy Treatment Options and Research (WETOR) Study Group, Women With Epilepsy Treatment Options and Research (WETOR) Study Group},
  title = {Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy},
  journal = {JAMA Neurology},
  year = {2023},
  doi = {10.1001/jamaneurol.2023.3400}
}
Kostenlos starten →